Afya Limited AFYA announced it has reached a total of 220 medical seats at Centro Universitário de Maceió (UNIMA Alagoas) after the recent authorization made by the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education. The authorization leads to an increase of 80 medical seats at UNIMA Alagoas, which is housed in the city of Maceió, located in Alagoas, Brazil. The increased medical seats will come with an additional payment of R$ 1.25 million per increased seat approval, updated by IPCA from Jan 2, 2023, until the payment date. Furthermore, the increased number of seats will contribute to the 3,583 approved seats of AFYA, thus strengthening its position to provide quality medical education in the country. Price Performance Shares of this medical education group and medical practice solutions provider in Brazil gained 5.6% in the past three months, outperforming the Zacks Schools industry’s 3.1% growth. The company’s focus on accretive buyouts, operational restructuring efforts and other business initiatives to offer top-tier medical education services are likely to continue boosting its growth in the upcoming period. Zacks Investment Research Image Source: Zacks Investment Research Considering the estimate revision trend, the Zacks Consensus Estimate for 2024 earnings per share (EPS) of AFYA has been revised upward to $1.63 from $1.60 in the past 30 days. The estimated figure indicates 27.3% year-over-year growth. Also, the estimate for second-quarter EPS has moved north in the past 60 days, indicating 27.6% growth from the year-ago quarter’s reported figure. The growth trend is solidified by a VGM Score of A, backed by a Value Score and Growth Score of A. Such an uptrend depicts analysts’ optimism about the stock’s potential. Zacks Rank & Other Key Picks Afya currently carries a Zacks Rank #2 (Buy). Here are other top-ranked stocks from the Consumer Discretionary sector. PlayAGS, Inc. AGS presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks Rank #1 stocks here. AGS has a trailing four-quarter earnings surprise of 33.3%, on average. The stock has surged 76% in the past year. The Zacks Consensus Estimate for AGS’ 2024 sales and EPS implies growth of 7.7% and 5,200%, respectively, from the year-ago levels. La-Z-Boy Incorporated LZB currently sports a Zacks Rank of 1. LZB has a trailing four-quarter earnings surprise of 15.3%, on average. The stock has gained 38.7% in the past year. The Zacks Consensus Estimate for LZB’s fiscal 2025 sales and EPS implies growth of 2.1% and 5%, respectively, from the year-ago levels. SharkNinja, Inc. SN currently carries a Zacks Rank of 2. SN has a trailing four-quarter earnings surprise of 12.2%, on average. The stock has risen 74.5% in the past year. The consensus estimate for SN’s 2024 sales and EPS indicates an increase of 11.8% and 18.6%, respectively, from the year-ago levels. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report La-Z-Boy Incorporated (LZB):Free Stock Analysis Report SharkNinja, Inc. (SN):Free Stock Analysis Report PlayAGS, Inc. (AGS):Free Stock Analysis Report Afya Limited (AFYA):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
AFYA's Medical Seats Increase to 220 at UNIMA Alagoas in Brazil
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...